Search clinical trials for: AVP-923-45

Total 5746 results

Avanir Pharmaceuticals

Completed

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

Multiple Sclerosis

United States
Avid Radiopharmaceuticals

Completed

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Alzheimer's Disease

United States
Avanir Pharmaceuticals

Completed

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Stroke | Parkinson's Disease | Traumatic Brain Injury | Alzheimer's Disease

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
University Hospital, Toulouse
Institut National de la Santé Et de la Recherche Médicale, France; Avid Radiopharmaceuticals

Completed

Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage (COGHIC-AV45)

Intracerebral Hemorrhage

France
University of California, San Francisco
Avid Radiopharmaceuticals; Alzheimer's Drug Discovery Foundation

Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Postoperative Cognitive Dysfunction

United States
Avanir Pharmaceuticals

Completed

A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers

Healthy

Australia
University Hospital, Montpellier

Completed

Narcolepsy Protect Against Alzheimer's Disease? (PROTECMAN)

Narcolepsy | Amyloid Pathology

France
Avanir Pharmaceuticals

Completed

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis (PRIME)

Multiple Sclerosis | Central Neuropathic Pain

United States, Spain, Czechia, Poland, Argentina
Chang Gung Memorial Hospital

Recruiting

The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome

Post-stroke Dementia, Vascular Mild Cognitive Impairment

Taiwan
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation

Alzheimers Disease

United States
Chang Gung Memorial Hospital

Unknown

Amyloid Accumulation After Mild Traumatic Brain Injury

Traumatic Brain Injury
Avanir Pharmaceuticals

Completed

Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers

Healthy

Australia
Chang Gung Memorial Hospital

Unknown

Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers ([18F]AV-45)

Alzheimer's Disease
Chang Gung Memorial Hospital

Completed

The Aging Brain and Cognition: Contribution of Vascular Injury, Amyloid Plaque and Tau Protein to Cognitive Dysfunction After Stroke

Post-stroke Dementia | Vascular Mild Cognitive Impairment

Taiwan
Avid Radiopharmaceuticals

Completed

Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment
Avid Radiopharmaceuticals

Completed

Evaluation of PET Scan Timing Relative to AV-45 Injection Time

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Healthy Volunteers

Alzheimer Disease

United States
Avanir Pharmaceuticals

Completed

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

Amyotrophic Lateral Sclerosis

United States
Avid Radiopharmaceuticals

Completed

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Progressive Cognitive Decline

United States
Avid Radiopharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Completed

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

Parkinson's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Physician Training Methods to Read Florbetapir-PET Scans

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer's Disease
Chang Gung Memorial Hospital

Completed

Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)

Major Depressive Disorder

Taiwan
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment

United States
Eli Lilly and Company

Completed

A Non-drug Methods Study in Participants With Alzheimer's Disease

Alzheimer's Disease

France
Avid Radiopharmaceuticals

Completed

Evaluation of Reader Training Processes

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

Alzheimer's Disease

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

Parkinson's Disease | Alzheimer's Disease | Dementia With Lewy Bodies

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Avid Radiopharmaceuticals

Completed

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

Mild Cognitive Impairment | Alzheimer's Disease

United States
University Hospital, Tours

Completed

PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO) (NIDeCo)

Alzheimer Disease | Mild Cognitive Impairment | Memory Complaint

France
Chang Gung Memorial Hospital

Completed

Novel Neuroimage Study in Tauopathies With Parkinsonism

Parkinsonism

Taiwan
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Samuel Gandy

Completed

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

Traumatic Brain Injury | Mild Cognitive Impairment | Chronic Traumatic Encephalopathy

United States
Columbia University
National Institute on Aging (NIA)

Completed

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

Chronic Kidney Disease | Endstage Renal Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Kevin Flanigan
Sarepta Therapeutics, Inc.

Completed

A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.

Duchenne Muscular Dystrophy

United States
Johns Hopkins University

Recruiting

Microvascular Plug (MVP) for the Treatment of Pulmonary ArterioVenous Malformations (PAVMs)

Pulmonary Arteriovenous Malformation

United States
Avid Radiopharmaceuticals

Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects (MCI)

Alzheimer's Disease

United States
Amgen

Completed

A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis
Oregon Center for Applied Science, Inc.
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety Skills Training For Parents of Preschool Children (Preschool_2)

Behavior

United States
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Completed

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Mild Cognitive Impairment (MCI) | Alzheimer's Disease (AD) | Significant Memory Concern (SMC) | Early Mild Cognitive Impairment (EMCI) | Late Mild Cognitive Impairment (LMCI)

United States, Canada
Avid Radiopharmaceuticals
General Electric; American College of Radiology Imaging Network

Completed

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Alzheimer's Disease

United States

Search clinical trials for: AVP-923-45

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations